Literature DB >> 9876974

Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy.

J W Christman1, L H Lancaster, T S Blackwell.   

Abstract

NF-kappaB is an important transcription factor complex that appears to play a fundamental role in regulating acute inflammation through activation of the cytokine cascade and production of other pro-inflammatory mediators. There is increasing evidence that NF-kappaB is important in the pathobiology of disease states such as SIRS, MODS and ARDS; therefore, therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction. Specific interventions that hold promise for suppressing NF-kappaB activation include the use of antioxidants, inhibition of NIK and the IKK signalsome, treatment with proteasome inhibitors, induction of endotoxin tolerance and, possibly the use of corticosteroids in selected patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876974      PMCID: PMC7094907          DOI: 10.1007/s001340050735

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  61 in total

1.  Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis.

Authors:  F Arnalich; E Garcia-Palomero; J López; M Jiménez; R Madero; J Renart; J J Vázquez; C Montiel
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Effect of Dachengqi decoction on NF-kappaB p65 expression in lung of rats with partial intestinal obstruction and the underlying mechanism.

Authors:  Shenglan Yang; Lin Shen; Yang Jin; Jianguo Liu; Jiechang Gao; Daoben Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

3.  Effects of sulfasalazine on lipid peroxidation and histologic liver damage in a rat model of obstructive jaundice and obstructive jaundice with lipopolysaccharide-induced sepsis.

Authors:  Musa Dirlik; Aydin Karahan; Hakan Canbaz; Mehmet Caglikulekci; Ayşe Polat; Lulufer Tamer; Suha Aydin
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

Review 4.  Sex differences and estrogen modulation of the cellular immune response after injury.

Authors:  Melanie D Bird; John Karavitis; Elizabeth J Kovacs
Journal:  Cell Immunol       Date:  2008-02-21       Impact factor: 4.868

5.  Blockade of nuclear factor-kappaB activation prevents hypodynamic shock and gastric hypoperfusion induced by endotoxin in anesthetized dogs.

Authors:  Chieko Mitaka; Yukio Hirata; Yutaka Narumi; Kuninori Yokoyama; Koshi Makita; Koichi Katsuyama; Takasuke Imai
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

6.  The role of calcium, NF-κB and NFAT in the regulation of CXCL8 and IL-6 expression in Jurkat T-cells.

Authors:  Hazem Khalaf; Jana Jass; Per-Erik Olsson
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

7.  Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial.

Authors:  R Gapski; J L Barr; D P Sarment; M G Layher; S S Socransky; W V Giannobile
Journal:  J Periodontol       Date:  2004-03       Impact factor: 6.993

8.  Effect of cholecystokinin octapeptide on tumor necrosis factor alpha transcription and nuclear factor-kappaB activity induced by lipopolysaccharide in rat pulmonary interstitial macrophages.

Authors:  Bin Cong; Shu-Jin Li; Yu-Xia Yao; Gui-Jun Zhu; Yi-Ling Ling
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Role of Shenfu Injection in rats with systemic inflammatory response syndrome.

Authors:  Jin Wang; Li-fen Qiao; Guang-tian Yang
Journal:  Chin J Integr Med       Date:  2008-06-21       Impact factor: 1.978

10.  Evaluation of early macrophage activation and NF-kappaB activity in pulmonary injury caused by deep hypothermia circulatory arrest: an experimental study.

Authors:  Jing-hao Zheng; Bo-tao Gao; Zu-ming Jiang; Xiao-qing Yu; Zhi-wei Xu
Journal:  Pediatr Cardiol       Date:  2009-12-03       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.